Unlocking New Treatment Horizons for Celiac Disease: PRKCD Revealed as a Promising Target through Mendelian
Jie Zhou1,2, Yixin Xu1,2, Haitao Wang3
1Department of Gastrointestinal Surgery, The Wujin Hospital Affiliated with Jiangsu University, Changzhou, China.
Endocrine, Metabolic & Immune Disorders Drug Targets
|September 5, 2025
Summary
Researchers identified 18 druggable genes causally linked to Celiac Disease (CeD). The PRKCD gene shows promise as a novel therapeutic target for CeD treatment, addressing a key unmet medical need.
Area of Science:
- Genetics
- Immunology
- Pharmacology
Background:
- Celiac Disease (CeD) is a serious autoimmune disorder with significant unmet needs for effective pharmacological treatments.
- Current management relies on strict gluten-free diets, which are challenging to maintain and do not fully resolve the condition for all patients.
Purpose of the Study:
- To identify druggable genes with a causal relationship to Celiac Disease (CeD) using genetic association data.
- To pinpoint novel therapeutic targets for CeD by analyzing large-scale genetic consortia data.
Main Methods:
- Mendelian Randomization (MR) analysis of summary statistics from eQTLGen and FinnGen Consortia for CeD.
- Identified CeD-associated genes using Inverse Variance Weighted (IVW) method with a False Discovery Rate (FDR) < 0.05.
- Validated findings through colocalization analysis and Summary-data-based Mendelian Randomization (SMR) analyses.
Main Results:
- Identified 18 druggable genes causally associated with CeD (FDR < 0.05).
- The PRKCD gene was highlighted as a significant potential therapeutic target for CeD (OR 1.319, P = 6.85E-07, FDR = 0.002).
- Results were robust, passing pleiotropy, heterogeneity, and sensitivity analyses.
Conclusions:
- This study is the first to identify the PRKCD gene as a potential therapeutic target for CeD.
- The findings offer new insights into CeD pathogenesis and guide the development of novel pharmacological treatments.
- Further experimental validation is needed to confirm PRKCD's role in CeD and its therapeutic potential.
Keywords:
Tight junctionsclaudinsdruggable genesintestinal barrier.protein kinase Csingle nucleotide polymorphismMore Related Videos
Related Concept Videos
01:16In-vitro Mutagenesis
14.8K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
14.8K
02:15M-Cdk Drives Transition Into Mitosis
5.3K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K
01:29Pharmacogenomics: Identification of New Drug Targets
119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119